Myricetin Clinical Trials

Size	Price	Qty
25mg	USD 147
100mg	USD 270

Clinical Trials

The clinical evaluation landscape for myricetin remains limited, highlighted by a clinical trial sponsored by the University of Padova. This completed, phase-unassigned study investigated the physiological impacts of myricetin in combination with other dietary compounds, specifically targeting oxidative stress and alcohol drinking by assessing blood alcohol levels and biomarkers of oxidative stress. Consequently, available data primarily underscores the compound's potential in modulating metabolic responses and oxidative burden.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06548503	COMPLETED	Oxidative Stress; Alcohol Drinking	University of Padova	2023-11-01

(data from https://clinicaltrials.gov, updated on 2024-08-12)

Check the Myricetin product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Myricetin acts as a natural flavonol inhibitor that targets MEK1 activity and binds PI3Kγ with a dissociation constant of 0.17 μM, thereby blocking downstream MAPK and lipid kinase signaling pathways to prevent cell transformation. Through this enzymatic inhibition combined with its intrinsic antioxidant capacity, myricetin mitigates cellular reactive oxygen species accumulation, offering a clear mechanistic rationale for clinical studies addressing oxidative stress and metabolic markers associated with alcohol drinking.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).